Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia

Psychiatric Quarterly

Volumn 80, Issue 4, 2009, Pages 241-249

  Mohamed, Somaia ^a,b,d   Rosenheck, Robert ^a,b   Harpaz Rotem, Ilan ^a,b   Leslie, Douglas ^c   Sernyak, Michael J ^a,b  

^a VA New England Mental Illness   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Antipsychotics; Medication adherence; Schizophrenia; Survival analysis

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 71449109074     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-009-9111-9     Document Type: Article

References (24)

1. WW Fleischhacker M Eerdekens K Karcher G Remington PM Llorca W Chrzanowski S Martin 2003 Gefvert O: Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic J Clin Psychiatr 64 10 1250 1257 1:CAS:528:DC%2BD3sXpsVWlsb0%3D
2. P Thieda S Beard A Richter 2003 Kane J: An economic review of compliance with medication therapy in the treatment of schizophrenia Psychiatr Serv 54 4 508 516 10.1176/appi.ps.54.4.508 10.1176/appi.ps.54.4.508 12663838 (Pubitemid 36752981)
3. M Valenstein LA Copeland FC Blow JF McCarthy JE Zeber L Gillon CR Bingham 2002 Stavenger T: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission Med Care 40 8 630 639 10.1097/00005650-200208000-00002 10.1097/00005650-200208000-00002 12187177
4. JM Kane 2006 Review of treatments that can ameliorate nonadherence in patients with schizophrenia J Clin Psychiatry 67 Suppl 5 9 14 1:CAS:528:DC%2BD28XlvFamu7c%3D 16822091
5. J Walburn R Gray K Gournay S Quraishi 2001 David AS: Systematic review of patient and nurse attitudes to depot antipsychotic medication Br J Psychiatry 179 300 307 10.1192/bjp.179.4.300 10.1192/bjp.179.4.300 1:STN:280: DC%2BD3Mrjtl2gsA%3D%3D 11581109 (Pubitemid 32996038)
6. B Zhu H Ascher-Svanum L Shi D Faries W Montgomery 2008 Marder SR: Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia Psychiatr Serv 59 3 315 317 10.1176/appi.ps.59.3.315 10.1176/appi.ps.59.3.315 18308914
7. Adams CE, Eisenbruch M: Depot fluphenazine for schizophrenia. Cochrane Database Syst Rev CD000307, 2000
8. GE Hogarty NR Schooler R Ulrich F Mussare P Ferro E Herron 1979 Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride Arch Gen Psychiatry 36 12 1283 1294 1:STN:280:DyaL3c%2FktFKhsQ%3D%3D 227340
9. MA Becker MS Young E Ochshorn 2007 Diamond RJ: The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia Adm Policy Ment Health 34 3 307 314 10.1007/s10488-006-0108-5 10.1007/s10488-006-0108-5 17211716 (Pubitemid 46742594)
10. CR Dolder JP Lacro LB Dunn 2002 Jeste DV: Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159 1 103 108 10.1176/appi.ajp.159.1.103 10.1176/appi.ajp.159.1.103 11772697 (Pubitemid 41070734)
11. JA Lieberman TS Stroup JP McEvoy MS Swartz RA Rosenheck DO Perkins RS Keefe SM Davis CE Davis BD Lebowitz J Severe 2005 Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 12 1209 1223 10.1056/NEJMoa051688 10.1056/NEJMoa051688 1:CAS:528: DC%2BD2MXhtVeltL%2FN 16172203 (Pubitemid 41345943)
12. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Swartz MS, Keefe R, Stroup TS, Lieberman JA: Extrapyramidal side effects of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic Schizophrenia. Br J Psychiatr (in press)
13. RA Rosenheck 2006 Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 63 10 1074 1076 10.1001/archpsyc.63.10.1074 10.1001/archpsyc.63.10.1074 17015809 (Pubitemid 44498386)
14. JP Lindenmayer E Eerdekens SA Berry 2004 Eerdekens M: Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics J Clin Psychiatry 65 8 1084 1089 1:CAS:528:DC%2BD2cXnvFKht7c%3D 15323593
15. OS Niaz 2007 Haddad PM: Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Acta Psychiatr Scand 116 1 36 46 10.1111/j.1600-0447.2006.00980.x 10.1111/j.1600-0447.2006.00980.x 1:CAS:528:DC%2BD2sXos1Khs7c%3D 17559599 (Pubitemid 46889775)
16. M Olfson SC Marcus 2007 Ascher-Svanum H: Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone Schizophr Bull 33 6 1379 1387 10.1093/schbul/sbm033 10.1093/schbul/sbm033 17470444 (Pubitemid 350022772)
17. DO Perkins 2002 Predictors of noncompliance in patients with schizophrenia J Clin Psychiatry 63 12 1121 1128 12523871
18. LM Arnold SM Strakowski ML Schwiers J Amicone DE Fleck KB Corey JE Farrow 2004 Sex, ethnicity, and antipsychotic medication use in patients with psychosis Schizophr Res 66 2-3 169 175 10.1016/S0920-9964(03)00102-6 10.1016/S0920-9964(03)00102-6 15061250 (Pubitemid 38041116)
19. M Valenstein LA Copeland R Owen FC Blow S Visnic 2001 Adherence assessments and the use of depot antipsychotics in patients with schizophrenia J Clin Psychiatry 62 7 545 551 1:STN:280:DC%2BD3Mvkt1ynsQ%3D%3D 11488366
20. JC West SC Marcus J Wilk LM Countis DA Regier M Olfson 2008 Use of depot antipsychotic medications for medication nonadherence in schizophrenia Schizophr Bull 34 5 995 1001 10.1093/schbul/sbm137 10.1093/schbul/sbm137 18093962
21. SN Ghaemi DJ Hsu KJ Rosenquist TB Pardo FK Goodwin 2006 Extrapyramidal side effects with atypical neuroleptics in bipolar disorder Prog Neuropsychopharmacol Biol Psychiatry 30 2 209 213 10.1016/j.pnpbp.2005.10.014 10.1016/j.pnpbp.2005.10.014 1:CAS:528:DC%2BD28XhvVWlu7k%3D 16412546 (Pubitemid 43288060)
22. WA Kinghorn JP McEvoy 2005 Aripiprazole: pharmacology, efficacy, safety and tolerability Expert Rev Neurother 5 3 297 307 10.1586/14737175.5.3.297 10.1586/14737175.5.3.297 1:CAS:528:DC%2BD2MXltlOnur0%3D 15938662 (Pubitemid 40705271)
23. D Taylor L Shapland G Laverick J Bond J Munro 2000 Clozapine - a survey of patient perceptions Psychiatr Bull 24 12 450 452 10.1192/pb.24.12.450 10.1192/pb.24.12.450 (Pubitemid 32011030)
24. NA Keks K Altson J Hope N Krapivensky C Culhane A Tanaghow P Doherty A Bootle 1999 Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service Aust N Z J Psychiatry 33 6 896 901 10.1046/j.1440-1614.1999.00639.x 10.1046/j.1440-1614.1999.00639.x 1:STN:280:DC%2BD3c%2FosVagtA%3D%3D 10619218